Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, Dec. 21 '25)

 


    Infect Control Hosp Epidemiol

  1. LI Q, Novosad S, Rha B, Hua H, et al
    Trends of bloodstream infection incidence rates among patients on outpatient hemodialysis, National Healthcare Safety Network, 2012-2021.
    Infect Control Hosp Epidemiol. 2025 Dec 18:1-7. doi: 10.1017/ice.2025.
    PubMed         Abstract available


    Int J Infect Dis

  2. CHOI WS, Kim KH, Kim DS, Lee SH, et al
    Increased 30-day Mortality Risk in Coronavirus Disease 2019 Compared to Seasonal Influenza.
    Int J Infect Dis. 2025 Dec 17:108312. doi: 10.1016/j.ijid.2025.108312.
    PubMed         Abstract available

  3. RODGERS MA, Averhoff F, Berg MG, Anderson M, et al
    Robust mission-driven responses to infectious disease threats delivered by the Abbott pandemic defense coalition.
    Int J Infect Dis. 2026;162:108162.
    PubMed         Abstract available


    J Med Virol

  4. WU Y, Yang C, Wei X, Xiao T, et al
    Albendazole Suppresses SARS-CoV-2 Replication by Enhancing HERC5-Mediated ISGylation of Nucleocapsid Protein.
    J Med Virol. 2025;97:e70751.
    PubMed         Abstract available


    J Virol

  5. FONSECA BF, Robinot R, Michel V, Mendez A, et al
    Stealth replication of SARS-CoV-2 Omicron in the nasal epithelium at physiological temperature.
    J Virol. 2025 Dec 19:e0200825. doi: 10.1128/jvi.02008.
    PubMed         Abstract available

  6. HAWKINS GM, Qing E, Salgado J, Chan P, et al
    A murine coronavirus infection platform identifies proviral and proinflammatory activities of SARS-CoV-2 accessory protein 7a.
    J Virol. 2025 Dec 16:e0196124. doi: 10.1128/jvi.01961.
    PubMed         Abstract available


    JAMA

  7. DEVANAND DP, Wisniewski T, Razlighi Q, Qian M, et al
    Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial.
    JAMA. 2025 Dec 17:e2521738. doi: 10.1001/jama.2025.21738.
    PubMed         Abstract available

  8. MCCLYMONT E, Blitz S, Forward L, Cole S, et al
    The Role of Vaccination in Maternal and Perinatal Outcomes Associated With COVID-19 in Pregnancy.
    JAMA. 2025 Dec 15:e2521001. doi: 10.1001/jama.2025.21001.
    PubMed         Abstract available


    Lancet

  9. RUTTER H, Wabnitz K, Nambiar D, Garde A, et al
    The Lancet Commission on improving population health post-COVID-19.
    Lancet. 2025 Dec 11:S0140-6736(25)02061-6. doi: 10.1016/S0140-6736(25)02061.
    PubMed        


    Lancet Infect Dis


  10. Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet Infect Dis. 2025 Dec 15:S1473-3099(25)00689.
    PubMed         Abstract available

Source: 

____

Comments

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...